Biocartis Group

Biocartis Group EBIT per Share

Delisted·Mar 13, 2026

The EBIT per Share of Biocartis Group (BCART.BR) as of Nov 17, 2026 is -0.75 EUR. In the previous year, EBIT per Share was -0.94 EUR — a change of -21.09% (higher).

EBIT per Share

-0.75EUR

YoY

-21.09%

Last updated:

EBIT per Share of Biocartis Group is 2022 -0.75 EUR. EBIT per Share of Biocartis Group was 2021 -0.94 EUR. It decreases by -21.09% higher compared to the previous year.

The Biocartis Group EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2018
-0.84 EUR
Jan 1, 2019
-0.86 EUR
Jan 1, 2020
-0.71 EUR
Jan 1, 2021
-0.94 EUR
Jan 1, 2022
-0.75 EUR
Jan 1, 2023 (e)
-0.57 EUR
Jan 1, 2024 (e)
-0.29 EUR
Jan 1, 2025 (e)
0.07 EUR
The Biocartis Group EBIT per Share history
YEAREBIT per ShareYoY
est0.07EUR-122.22%
est-0.29EUR-48.57%
est-0.57EUR-23.37%
-0.75EUR-21.09%
-0.94EUR+32.13%
-0.71EUR-16.99%
-0.86EUR+3.02%
-0.84EUR-1.90%
-0.85EUR-23.34%
-1.11EUR+21.78%
-0.91EUR+48.35%
-0.62EUR+10.62%
-0.56EUR-37.17%
-0.89EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biocartis Group Stock analysis

What does Biocartis Group do? Biocartis Group NV is a Belgian biotechnology company specializing in the development and marketing of innovative diagnostic test systems. The company was founded in 2007 and is headquartered in Mechelen, Belgium. Biocartis focuses on various disease areas such as gynecology, oncology, infectious diseases, and immunology. Biocartis' business model is based on a unique diagnostic test system called Idylla, which allows for rapid testing within hours instead of the usual weeks. The Idylla platform also offers high accuracy in identifying biomarkers and easy handling for medical personnel. The company has certified distribution partners worldwide to support the marketing and sales of Biocartis products. Biocartis collaborates closely with pharmaceutical companies, medical laboratories, and clinics globally to deliver the best results for its customers. The company also has partnerships with other biotech companies like Merck and Genomic Health to support the development of its diagnostic tests. Biocartis offers a wide range of diagnostic tests for various cancer types, gynecology, and infectious diseases. Their tests help physicians identify the type and extent of tumors and monitor patients' health status. Through the development and marketing of innovative diagnostic test systems, Biocartis aims to improve disease diagnosis and monitoring, ultimately enhancing treatment for patients worldwide. Overall, Biocartis is a leading company in the biotechnology industry specializing in the development and marketing of innovative diagnostic test systems for various disease areas. With its certified distribution partners and partnerships with other biotech companies, Biocartis has a strong presence in the global market and is well positioned to continue being a key player in the biomedical diagnostics industry. Biocartis Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biocartis Group stock

EBIT per Share of Biocartis Group is -0.75 EUR in 2022.

EBIT per Share of Biocartis Group changed from -0.94 EUR to -0.75 EUR, representing a -21.09% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Biocartis Group since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Biocartis Group

All Key Metrics — Biocartis Group